{"denomUnitsSelected":"Participants","description":"Blood samples were collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. Per protocol, the number of participants who developed anti pembrolizumab antibodies were reported.","reportingStatus":"NOT_POSTED","timeFrame":"Predose and Postdose on Day 1 of Cycles 1 through 18 (up to approximately 28 months). Each cycle is 6 weeks.","title":"Number of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab","type":"SECONDARY"}